Harvard Apparatus Regenerative Technology, Inc.

Form 4

November 05, 2013

FOI	RM	4
------------	----	---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL OMB

3235-0287 Number: January 31,

2005 Estimated average

0.5

burden hours per response...

Expires:

Check this box if no longer subject to Section 16.

SECURITIES Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. See Instruction

30(h) of the Investment Company Act of 1940 1(b).

(Middle)

(Zip)

(Print or Type Responses)

1. Name and Address of Reporting Person * KENNEDY JOHN F

2. Issuer Name and Ticker or Trading

Symbol

Harvard Apparatus Regenerative Technology, Inc. [HART]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) 3. Date of Earliest Transaction

(Month/Day/Year) 11/01/2013

X_ Director 10% Owner Officer (give title Other (specify

C/O HARVARD APPARATUS REGENERATIVE TECH., 84 OCTOBER HILL ROAD

> (Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

D

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

HOLLISTON, MA 01746

(City)

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3) (Month/Day/Year)

(State)

11/01/2013

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported

Transaction(s) (Instr. 3 and 4) 6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)

Code V Amount (D) Price

1,950

J \$0 1,950 D

Common Stock

Stock

Common

11/01/2013

J 635 ⁽²⁾ A \$0 $2.585^{(3)}$

(A)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

$\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (\emph{e.g.}, puts, calls, warrants, options, convertible securities) \\ \end{tabular}$

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number Transaction Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$ 4.31	11/01/2013		J		277 (2)		<u>(4)</u>	05/25/2016	Common Stock, par value \$0.01 per share	277
Stock option (right to buy)	\$ 4.75	11/01/2013		J		139		<u>(5)</u>	06/04/2014	Common Stock, par value \$0.01 per share	139
Stock option (right to buy)	\$ 3.08	11/01/2013		J		1,109 (2)		<u>(6)</u>	05/26/2015	Common Stock, par value \$0.01 per share	1,109
Stock option (right to buy)	\$ 5.31	11/01/2013		J		279 (2)		<u>(7)</u>	05/24/2017	Common Stock, par value \$0.01 per share	279
Stock option (right to buy)	\$ 4.89	11/01/2013		J		277 (2)		<u>(8)</u>	05/22/2018	Common Stock, par value \$0.01 per share	277
Stock option (right to buy)	\$ 3.27	11/01/2013		J		999 (2)		<u>(9)</u>	05/21/2019	Common Stock, par value \$0.01 per share	999
Stock option	\$ 3.71	11/01/2013		J		950 (2)		(10)	06/04/2020	Common Stock, par	950

8. I De Sec (In

(right to buy)							value \$0.01 per share	
Stock option (right to buy)	\$ 5.79	11/01/2013	J	997	(11)	06/02/2021	Common Stock, par value \$0.01 per share	997
Stock option (right to buy)	\$ 3.67	11/01/2013	J	893 (2)	<u>(12)</u>	06/01/2022	Common Stock, par value \$0.01 per share	893
Stock option (right to buy)	\$ 5.22	11/01/2013	J	631 (2)	(13)	05/31/2023	Common Stock, par value \$0.01 per share	631

Reporting Owners

eporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			

KENNEDY JOHN F C/O HARVARD APPARATUS REGENERATIVE TECH. 84 OCTOBER HILL ROAD HOLLISTON, MA 01746

X

Relationshins

Signatures

/s/ John F. 11/05/2013 Kennedy

**Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- stock dividend distributed by Harvard Bioscience on November 1, 2013 to effectuate its spin-off of the Issuer. The Reporting Person was entitled to receive the dividend of the Issuer's common stock from Harvard Bioscience because Reporting Person held 7,801 shares of common stock of Harvard Bioscience on the record date for the spin-off, being October 21, 2013. Each holder of record was entitled to receive one share of the Issuer's common stock for every four shares of Harvard Bioscience common stock owned by such holder on such record date.

Reflects the shares of the Issuer's common stock issued to the reporting person from Harvard Bioscience, Inc. pursuant to the common

(2) These options and restricted stock units were acquired by the Reporting Person in connection with the adjustment to the existing options and restricted stock units held by the Reporting Person and issued by Harvard Bioscience, Inc. These issuances by the Issuer to the Reporting Person were required in connection with the spin-off of the Issuer by Harvard Bioscience. The share amounts and exercise prices of these options and restricted stock units issued by the Issuer were set in a manner to ensure the intrinsic value held by the Reporting Person pertaining to the existing awards issued by Harvard Bioscience was maintained immediately following the spin-off. In

Reporting Owners 3

addition to these grants by the Issuer, to maintain such intrinsic value, adjustments to the existing equity awards issued by Harvard Bioscience were also made in favor of the Reporting Person.

- Includes (a) a deferred stock award of 309 restricted stock units which shall fully vest on May 31, 2014; and (b) a deferred stock award of 326 restricted stock units which vest in equal installments on June 1, 2014 and June 1, 2015; and (c) 1,950 shares of common stock held by the Reporting Person.
- (4) The option shares vested in three equal installments on May 25, 2007, 2008 and 2009.
- (5) The option shares vested in three equal installments on June 4, 2005, 2006 and 2007.
- (6) The option shares vested in three equal installments on May 26, 2006, 2007 and 2008.
- (7) The option shares vested in three equal installments on May 24, 2008, 2009 and 2010.
- (8) The option shares vested in three equal installments on May 22, 2009, 2010 and 2011.
- (9) The option shares vested in three equal installments on May 21, 2010, 2011 and 2012.
- (10) The option shares vested in three equal installments on June 4, 2011, 2012 and 2013.
- (11) The option shares vest in three equal installments on June 2, 2012, 2013 and 2014.
- (12) The option shares vest in three equal installments on June 1, 2013, 2014 and 2015.
- (13) The options shall fully vest on May 31, 2014.

Remarks:

This form has been signed under power of attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. 1451 W. Cypress Road, Suite 300 Ft. Lauderdale, FL 33309 Item 2(a)Name of Person Filing: MACHIAVELLI LTD LLC (b)Address of Principal Office, or if None, Residence: 1111 Alderman Dr., Suite 210 Alpharetta, Ga 30005 (c) Citizenship: United States (d)Title of Class of Securities: Common Stock, \$0.00001 par value per share (e)CUSIP Number:

Item 3 a: If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is

Not Applicable

Item 4 Ownership:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 110,000,000
- (b) Percent of Class: 9.08%

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote: 110,000,000
- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of:

110,000,000

(iv) Shared power to dispose or to direct the disposition of:

Page 3 of 5 Pages

Item Compariship of Five Percent or Less of a Class:

Not Applicable

Ownership of More than Five Percent on Behalf of Another Person:

Not Applicable

Item Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

Not Applicable

Item o Identification and Classification of Members of the Group:

Not Applicable

Notice of Dissolution of Group:

Not Applicable

Item 10 Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 4 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 28, 2015 /s/ Joseph C. Canouse
Joseph C. Canouse

Page 5 of 5 Pages